Why in the News?

Antimicrobial resistance (AMR) has become a serious global public health threat as the development of new antibiotics has not kept pace with the rapid rise in drug resistance. Unlike earlier decades, when ineffective antibiotics were regularly replaced by new ones, no truly new antibiotic classes have emerged in recent years. India is among the worst affected, with very high antibiotic use and an estimated 2.74 lakh deaths linked to AMR in 2019.

Why is antimicrobial resistance a growing public health crisis?

1. Rising mortality burden: AMR-attributable deaths in India were estimated at 2.74 lakh in 2019, reflecting a large and growing health burden.
2. Treatment failure: Common infections are increasingly difficult to treat, increasing complications, hospital stays, and mortality.
3. Systemic impact: AMR undermines surgery, chemotherapy, organ transplants, and neonatal care by increasing infection risk.
4. Global spread: Resistant pathogens spread rapidly through travel, trade, food chains, and the environment.

Why is India disproportionately affected by AMR?

1. High infectious disease load: India continues to face a high burden of communicable diseases requiring antibiotic use.
2. Extensive antibiotic consumption: India is among the world’s largest consumers of antibiotics, both in human and animal health.
3. Healthcare pressures: Overcrowded hospitals and limited diagnostic capacity encourage empirical and broad-spectrum antibiotic use.
4. Survival advantage of pathogens: Drug-resistant bacteria survive treatment and transmit resistance genes to other bacteria.

How does antibiotic misuse accelerate resistance?

1. Inappropriate prescribing: Antibiotics are frequently used for viral infections such as colds, coughs, and diarrhoea.
2. Empirical treatment: Lack of timely diagnostics leads to blind antibiotic use without pathogen identification.
3. Prophylactic use: Antibiotics are prescribed preventively, even where clinical benefit is uncertain.
4. Seasonal misuse: Antibiotics are used for seasonal viral illnesses due to patient demand and prescribing habits.

What is happening to the global antibiotic pipeline?

1. Limited innovation: Very few new antibiotic classes have been developed in the past three decades.
2. R&D stagnation: Most recent approvals involve modifications of existing drugs rather than new mechanisms of action.
3. Commercial disincentives: Antibiotics offer low returns compared to chronic disease drugs, discouraging private investment.
4. Effectiveness erosion: Even newly introduced antibiotics lose effectiveness rapidly due to resistance.

Why is antibiotic stewardship more effective than blanket bans?

1. Behavioural regulation: Stewardship programs guide rational prescribing rather than eliminating access.
2. Evidence from India: The Indian Council of Medical Research (ICMR) launched a national antibiotic stewardship programme in 2015.
3. Measured impact: Prescription awareness improved, but full behavioural internalisation remains limited.
4. Sustainability challenge: Stewardship requires continuous monitoring, training, and institutional commitment.

How do livestock and agriculture worsen the AMR problem?

1. Non-therapeutic use: Antibiotics are used in animals for growth promotion and disease prevention.
2. Shared drug classes: Many antibiotics critical for humans are also used in animals.
3. Environmental spread: Antibiotic residues enter soil and water through animal waste and food chains.
4. Resistance transfer: Resistance genes move between human, animal, and environmental bacteria.

Why is data collection on AMR inadequate?

1. Limited surveillance: ICMR’s AMR surveillance network covers only 25 tertiary hospitals.
2. Urban bias: Most data originates from large hospitals, missing community-level resistance patterns.
3. Underestimation risk: Resistance prevalence is likely higher than reported due to incomplete coverage.
4. Policy constraint: Inadequate data limits targeted interventions and resource allocation.

Why can’t new antibiotics alone solve AMR?

1. Rapid resistance development: Resistance emerges even against newly introduced drugs.
2. Finite effectiveness window: Antibiotics lose usefulness within a few years of widespread use.
3. Overreliance risk: Dependence on drug discovery ignores behavioural and systemic drivers.
4. Adjunct necessity: Stewardship, infection prevention, and diagnostics remain central.

Conclusion

The antibiotic pipeline crisis reflects a structural mismatch between rising resistance and declining innovation. India’s experience demonstrates that stewardship, surveillance, and behavioural regulation are as critical as drug discovery. Without systemic correction, modern medicine risks returning to a pre-antibiotic era.

PYQ Relevance

[UPSC 2024] Can overuse and free availability of antibiotics without Doctor’s prescription, be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

Linkage: This question directly maps to GS Paper III (Science & Technology-Public Health), aligning with UPSC’s repeated focus on antimicrobial resistance as a governance and regulatory challenge. It links with PYQs on antibiotic overuse, emerging health challenges, and technology-policy gaps, reflecting UPSC’s trend of testing systemic failures rather than medical details.